These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 26869522)

  • 21. Successful pregnancy outcome following gamete intra-Fallopian transfer in a patient with Müllerian dysgenesis.
    Lee CS; Lie AT
    Reprod Biomed Online; 2012 May; 24(5):547-9. PubMed ID: 22410277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study.
    Kol S; Humaidan P; Itskovitz-Eldor J
    Hum Reprod; 2011 Oct; 26(10):2874-7. PubMed ID: 21784738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibin and estradiol responses to ovarian hyperstimulation: effects of age and predictive value for in vitro fertilization outcome.
    Hughes EG; Robertson DM; Handelsman DJ; Hayward S; Healy DL; de Kretser DM
    J Clin Endocrinol Metab; 1990 Feb; 70(2):358-64. PubMed ID: 2298853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.
    European Recombinant LH Study Group
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2607-18. PubMed ID: 11397861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High exposure to progesterone between the end of menstruation and the day of triggering final oocyte maturation is associated with a decreased probability of pregnancy in patients treated by in vitro fertilization and intracytoplasmic sperm injection.
    Kyrou D; Kolibianakis EM; Fatemi HM; Camus M; Tournaye H; Tarlatzis BC; Devroey P
    Fertil Steril; 2011 Oct; 96(4):884-8. PubMed ID: 21843888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value of serum inhibin B measurement in predicting ovarian response in controlled ovarian hyperstimulation for in vitro fertilization cycle].
    Chen Y; Yu Q; Zhang YW; He FF; Sun ZY
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):368-71. PubMed ID: 16831355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Thomas S
    Fertil Steril; 2008 Jul; 90(1):231-3. PubMed ID: 17981269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of different doses of letrozole on the incidence of early-onset ovarian hyperstimulation syndrome after oocyte retrieval.
    He Q; Liang L; Zhang C; Li H; Ge Z; Wang L; Cui S
    Syst Biol Reprod Med; 2014 Dec; 60(6):355-60. PubMed ID: 25192259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimal precycle testing and ongoing cycle monitoring for in vitro fertilization and fresh pre-embryo transfer do not compromise fertilization, implantation, or ongoing pregnancy rates.
    Strawn EY; Roesler M; Rinke M; Aiman EJ
    Am J Obstet Gynecol; 2000 Jun; 182(6):1623-8. PubMed ID: 10871488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using the ovarian sensitivity index to define poor, normal, and high response after controlled ovarian hyperstimulation in the long gonadotropin-releasing hormone-agonist protocol: suggestions for a new principle to solve an old problem.
    Huber M; Hadziosmanovic N; Berglund L; Holte J
    Fertil Steril; 2013 Nov; 100(5):1270-6. PubMed ID: 23931964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.
    Yıldız GA; Şükür YE; Ateş C; Aytaç R
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():66-70. PubMed ID: 25238659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro oocyte maturation for safer treatment of infertility. The risk of ovarian overstimulation syndrome is minimized].
    Hreinsson J; Fridström M
    Lakartidningen; 2004 Nov; 101(46):3665-8, 3671. PubMed ID: 15586490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases.
    Gurbuz AS; Deveer R; Ozcimen N; Ozcimen EE; Lawrenz B; Banker M; Garcia-Velasco JA; Fatemi HM
    Gynecol Endocrinol; 2016; 32(1):18-20. PubMed ID: 26487486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral oestradiol supplementation as luteal support in IVF/ICSI cycles: a prospective, randomized controlled study.
    Lin H; Li Y; Li L; Wang W; Zhang Q; Chen X; Yang D
    Eur J Obstet Gynecol Reprod Biol; 2013 Apr; 167(2):171-5. PubMed ID: 23287635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flexible ovarian stimulation in a poor responder: a case report and literature review.
    Xu B; Li Y
    Reprod Biomed Online; 2013 Apr; 26(4):378-83. PubMed ID: 23497915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Menstrual cycle synchronization, ovarian stimulation, and in vitro fertilization in olive baboons (Papio anubis): a prospective randomized study.
    Nyachieo A; Spiessens C; Chai DC; Mwenda JM; D'Hooghe TM
    Fertil Steril; 2009 Feb; 91(2):602-10. PubMed ID: 18328482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.